Altamira Therapeutics Publishes Preclinical Data For Treatment Of Abdominal Aortic Aneurysm With SOD2 mRNA Delivered By SemaPhore Nanoparticles
Portfolio Pulse from Benzinga Newsdesk
Altamira Therapeutics has published preclinical data showing that their SemaPhore nanoparticles delivering SOD2 mRNA significantly reduce aorta dilation, delay rupture, and lower mortality in an animal model of abdominal aortic aneurysm. The positive outcomes suggest potential use in managing small abdominal aortic aneurysms and preventing ruptures.
July 19, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altamira Therapeutics' preclinical data on SemaPhore nanoparticles delivering SOD2 mRNA shows promising results in treating abdominal aortic aneurysm, potentially leading to new treatment options.
The positive preclinical data suggests a significant advancement in the treatment of abdominal aortic aneurysms, which could lead to increased investor confidence and a potential rise in stock price for Altamira Therapeutics (CYTO).
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100